Systemic, asymptomatic skeletal muscle infiltration by MALT lymphoma: Defining a 'silent infiltrator' phenotype with 18F-FDG PET/CT

IF 0.8 Q4 HEMATOLOGY
Leukemia Research Reports Pub Date : 2026-01-01 Epub Date: 2026-02-20 DOI:10.1016/j.lrr.2026.100573
Yasuyuki Takahashi , Ken Naganuma , Yuka Tanaka , Noriyuki Sakata , Taisuke Kawada , Masahiro Kizaki , Shuji Momose , Morihiro Higashi , Takayuki Tabayashi
{"title":"Systemic, asymptomatic skeletal muscle infiltration by MALT lymphoma: Defining a 'silent infiltrator' phenotype with 18F-FDG PET/CT","authors":"Yasuyuki Takahashi ,&nbsp;Ken Naganuma ,&nbsp;Yuka Tanaka ,&nbsp;Noriyuki Sakata ,&nbsp;Taisuke Kawada ,&nbsp;Masahiro Kizaki ,&nbsp;Shuji Momose ,&nbsp;Morihiro Higashi ,&nbsp;Takayuki Tabayashi","doi":"10.1016/j.lrr.2026.100573","DOIUrl":null,"url":null,"abstract":"<div><div>We report a rare phenotype of Stage IV extranodal marginal zone lymphoma (MALT lymphoma) manifesting as diffuse, asymptomatic skeletal muscle and bone marrow infiltration in a 60-year-old female. Despite a high tumor burden and intense ¹⁸F-FDG avidity (SUVmax 8.8), muscle enzymes remained normal, indicating a non-destructive \"silent infiltrator\" growth pattern. The diagnosis was confirmed via biopsy (CD20+, CD5-, CyclinD1-) and negative MYD88 L265P mutation status, excluding lymphoplasmacytic lymphoma. The patient achieved a Complete Metabolic Response following Bendamustine-Rituximab therapy. This case underscores the utility of PET/CT in detecting occult systemic disease and defines a unique, indolent clinical variant of muscular MALT lymphoma.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"25 ","pages":"Article 100573"},"PeriodicalIF":0.8000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213048926000130","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/2/20 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

We report a rare phenotype of Stage IV extranodal marginal zone lymphoma (MALT lymphoma) manifesting as diffuse, asymptomatic skeletal muscle and bone marrow infiltration in a 60-year-old female. Despite a high tumor burden and intense ¹⁸F-FDG avidity (SUVmax 8.8), muscle enzymes remained normal, indicating a non-destructive "silent infiltrator" growth pattern. The diagnosis was confirmed via biopsy (CD20+, CD5-, CyclinD1-) and negative MYD88 L265P mutation status, excluding lymphoplasmacytic lymphoma. The patient achieved a Complete Metabolic Response following Bendamustine-Rituximab therapy. This case underscores the utility of PET/CT in detecting occult systemic disease and defines a unique, indolent clinical variant of muscular MALT lymphoma.

Abstract Image

MALT淋巴瘤系统性、无症状骨骼肌浸润:18F-FDG PET/CT定义“无症状浸润者”表型
我们报告一个罕见的IV期结外边缘区淋巴瘤(MALT淋巴瘤)的表型,表现为弥漫性,无症状的骨骼肌和骨髓浸润。尽管高肿瘤负荷和强烈的¹⁸F-FDG依赖性(SUVmax 8.8),肌肉酶仍保持正常,表明非破坏性的“沉默浸润”生长模式。通过活检(CD20+, CD5-, CyclinD1-)和MYD88 L265P阴性突变状态确认诊断,排除淋巴浆细胞性淋巴瘤。患者在苯达莫司汀-利妥昔单抗治疗后获得完全代谢缓解。本病例强调了PET/CT在检测隐蔽性全身性疾病中的应用,并定义了一种独特的、惰性的肌性MALT淋巴瘤临床变体。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Leukemia Research Reports
Leukemia Research Reports Medicine-Oncology
CiteScore
1.70
自引率
0.00%
发文量
70
审稿时长
23 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书